<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101465400</journal-id>
<journal-id journal-id-type="pubmed-jr-id">34171</journal-id>
<journal-id journal-id-type="nlm-ta">Sci Signal</journal-id>
<journal-id journal-id-type="iso-abbrev">Sci Signal</journal-id>
<journal-title-group>
<journal-title>Science signaling</journal-title>
</journal-title-group>
<issn pub-type="ppub">1945-0877</issn>
<issn pub-type="epub">1937-9145</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31615899</article-id>
<article-id pub-id-type="pmc">7192243</article-id>
<article-id pub-id-type="doi">10.1126/scisignal.aay0300</article-id>
<article-id pub-id-type="manuscript">NIHMS1580883</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Impaired regulation of KCC2 phosphorylation leads to neuronal network dysfunction and neurodevelopmental pathology</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Pisella</surname>
<given-names>Lucie I.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gaiarsa</surname>
<given-names>Jean-Luc</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Diabira</surname>
<given-names>Diabé</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Jinwei</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Khalilov</surname>
<given-names>Ilgam</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Duan</surname>
<given-names>JingJing</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="author-notes" rid="FN1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kahle</surname>
<given-names>Kristopher T.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Medina</surname>
<given-names>Igor</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Aix- Marseille University UMR 1249, INSERM (Institut National de la Santé et de la Recherche Médicale) Unité 1249, INMED (Institut de Neurobiologie de la Méditerranée), Marseille, France.</aff>
<aff id="A2"><label>2</label>Institute of Biomedical and Clinical Sciences, College of Medicine and Health, University of Exeter Medical School, Hatherly Laboratories, Exeter, EX4 4PS, UK.</aff>
<aff id="A3"><label>3</label>Laboratory of Neurobiology, Kazan Federal University, Kazan 420008, Russia</aff>
<aff id="A4"><label>4</label>Department of Neurobiology, Howard Hughes Medical Institute, Boston Children’s Hospital, Boston, MA 02115, USA.</aff>
<aff id="A5"><label>5</label>Departments of Neurosurgery, Pediatrics, and Cellular &amp; Molecular Physiology; and Centers for Mendelian Genomics, Yale School of Medicine, New Haven, CT 06510, USA.</aff>
<author-notes>
<fn fn-type="present-address" id="FN1">
<label>†</label>
<p id="P1">Current address: Human Aging Research Institute (HARI), School of Life Sciences, Nanchang University, 999 Xuefu Road, Nanchang, Jiangxi, China. 330031</p>
</fn>
<fn fn-type="con" id="FN2">
<p id="P2"><bold>Author contributions:</bold> L.I.P., J-L.G. and I.M. designed research, performed experiments and wrote the paper. K.T.K. designed research and wrote the paper. J.Z., D.D. and I.K. performed experiments. J.D., L.I.P., I.M. bred the colony.</p>
</fn>
<corresp id="CR1"><label>*</label>Corresponding author. <email>igor.medyna@inserm.fr</email> (I.M.); <email>kristopher.kahle@yale.edu</email> (K.T.K.).</corresp>
<fn fn-type="COI-statement" id="FN3">
<p id="P61"><bold>Competing interests:</bold> The authors declare that they have no competing interests.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>5</day>
<month>4</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<day>15</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>30</day>
<month>4</month>
<year>2020</year>
</pub-date>
<volume>12</volume>
<issue>603</issue>
<elocation-id>eaay0300</elocation-id>
<abstract id="ABS1">
<p id="P3">KCC2 is a vital neuronal K<sup>+</sup>/Cl<sup>−</sup> co-transporter that is implicated in the etiology of numerous neurological diseases. In normal cells, KCC2 undergoes developmental dephosphorylation at Thr<sup>906</sup> and Thr<sup>1007</sup>. We engineered mice with heterozygous phospho-mimetic mutations T906E and T1007E (<italic>KCC2</italic><sup><italic>E</italic>/+</sup>) to prevent the normal developmental dephosphorylation of these sites. Immature (postnatal day 15) but not juvenile (postnatal day 30) <italic>KCC2</italic><sup><italic>E</italic>/+</sup> mice exhibited altered GABAergic inhibition, an increased glutamate/GABA synaptic ratio, and greater susceptibility to seizure. <italic>KCC2</italic><sup><italic>E</italic>/+</sup> mice also had abnormal ultra-sonic vocalizations at postnatal days 10 to 12 and impaired social behavior at postnatal day 60. Postnatal bumetanide treatment restored network activity by postnatal day 15 but failed to restore social behavior even by postnatal day 60. Our data indicate that posttranslational KCC2 regulation controls the GABAergic developmental sequence in vivo, indicating that deregulation of KCC2 could be a risk factor for the emergence of neurological pathology.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>